Pharmabiz8h
VYNE Therapeutics Announces US FDA clears VYNE Therapeutics’ IND application for VYN202, a novel BD2-selective BET inhibitor
VYNE Therapeutics Announces US FDA clears VYNE Therapeutics’ IND application for VYN202, a novel BD2-selective BET inhibitor: Bridgewater, New Jersey Wednesday, May 8, 2024, 18: ...
Pharmabiz8h
Apollo Cancer Centre performs Karnataka’s first robotic surgical technique to treat breast cancer
Apollo Cancer Centre (ACC), successfully conducted Karnataka’s first Robotic Nipple Sparing Mastectomy (RNSM), an advanced surgical technique to treat breast cancer. In India, breast cancer rates are ...
Pharmabiz9h
Narayana Health performs stem cell transplant for toddler with Down's syndrome and leukaemia
Narayana Health City has performed a stem cell transplant for toddler with Down's syndrome and acute myeloid leukaemia (AML). The hospital said that it highlights the expertise of its team in tackling ...
Pharmabiz9h
ZygoFix’s zLOCK Lumbar Facet Fixation System receives US FDA clearance
ZygoFix’s zLOCK Lumbar Facet Fixation System receives US FDA clearance: Misgav, Israel Wednesday, May 8, 2024, 17:00 Hrs [IST] ZygoFix Ltd, a portfolio company of The Trendlines ...
Pharmabiz10h
US FDA accepts Bristol Myers Squibb’s BLA for subcutaneous Nivolumab
US FDA accepts Bristol Myers Squibb’s BLA for subcutaneous Nivolumab: Princeton, New Jersey Wednesday, May 8, 2024, 16:00 Hrs [IST] Bristol Myers Squibb announced that the US Fo ...
Pharmabiz11h
Gossamer Bio, Chiesi Group ink collaboration to develop & commercialize seralutinib in PAH, PH-ILD & other indications
Gossamer Bio, Chiesi Group ink collaboration to develop & commercialize seralutinib in PAH, PH-ILD & other indications: San Diego, California Wednesday, May 8, 2024, 15:00 Hrs [IS ...
Pharmabiz12h
AstraZeneca withdraws Covid-19 vaccine Vaxzevria globally
Anglo-Swedish drug manufacturer AstraZeneca has said that it has started withdrawal of its Covid-19 vaccine Vaxzevria globally, owing to surplus of available updated vaccines in the market. The ...
Pharmabiz12h
Edgewise Therapeutics begins patient dosing in phase 2 CIRRUS-HCM trial of EDG-7500 in obstructive hypertrophic cardiomyopathy
Edgewise Therapeutics begins patient dosing in phase 2 CIRRUS-HCM trial of EDG-7500 in obstructive hypertrophic cardiomyopathy: Boulder, Colorado Wednesday, May 8, 2024, 14:00 Hrs ...
Pharmabiz12h
Birla Fertility & IVF acquires ARMC IVF fertility chain
Birla Fertility & IVF, one of India’s leading IVF networks, a part of the US$ 2.9 billion C K Birla Group, announced its acquisition of ARMC IVF Fertility Centre, marking the network's entry into ...
Pharmabiz13h
BioVersys expands collaboration with GSK to speed up development of alpibectir for treatment of tuberculosis
BioVersys expands collaboration with GSK to speed up development of alpibectir for treatment of tuberculosis: Basel, Switzerland Wednesday, May 8, 2024, 13:00 Hrs [IST] BioVersys ...
Pharmabiz14h
Purdue Pharma partners with MMCAP Infuse to provide low-cost opioid use disorder treatment to correctional facilities for incarcerated individuals
Purdue Pharma L.P. (Purdue) announced that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone), a medication for opioid use disorder (MOUD ...
Pharmabiz15h
ECDC, ECHA, EEA, EFSA, & EMA publish joint framework for action to support the implementation of One Health agenda in EU
ECDC, ECHA, EEA, EFSA, & EMA publish joint framework for action to support the implementation of One Health agenda in EU: Amsterdam, The Netherlands Wednesday, May 8, 2024, 11:00 ...